Elbe Klinikum Buxtehude, Germany Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2003
NCT00226408
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Elbeklinikum, Buxtehude, Germany

Active Ingredients

Drugs in Phase 3 Trials (1)

interferon alpha-2b (Intron-A) (1 trial)

Drugs in Phase 2 Trials (1)

Aviscumine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Melanoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2